FRI0428 Anti –tnf-a therapy and arterial stiffness in anklosing spondylitis; results with long-term 2 year- follow-up. (23rd January 2014)

• Record Type: Journal Article
• Authors: çapkin, E.; Karkucak, M.; Kırıs, A.; Şahin, M.; Kucukali turkyılmaz, A.; Karaca, A.; Gökmen, F.; Ayar, A.
• Is Part Of: Annals of the rheumatic diseases. Volume 72:Supplement 3(2013)
• Page Start: A519
• Page End: A519
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2013-eular.1555
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Anti-TNF-α are effectively used in management of AS, a chronic disease with increased risk of future cardiovascular events, but influence and additional benefit of these agents on arterial stiffness, a potentially modifiable risk marker for cardiovascular events, is controversial. Objectives: Our aim was to evaluate the long term effectiveness on arterial stiffness [pulse wave velocity (PVW)] treated anti-TNF alpha treatment in AS. Our initial follow-up (24 week) study on the effectiveness of anti-TNF-α therapy on arterial stiffness in AS did not demonstrate any clear benefit, and since optimal follow-up period for observing this effect remains unknown we aimed to document further follow-up of these patients at 2 years. Methods: A total 28 active AS patients (21 male, 7 female) were enrolled before initiation of biological therapy and their mid-term (24 weeks) evaluation was reported. For further evaluation initially reported patients were contacted 2 years after anti-TNF-α therapy, and arterial stiffness was assessed by using PWV Results: After 2 year of anti-TNF-α therapy, despite significant improvements in patients' symptoms and clinical activity parameters including BASDAI score, erythrocyte sedimentation rate and C-reactive protein (p=0.001, p=0.015, p=0.001, respectively) no significant change was obtained in arterial stiffness parameters (7.9 ± 1.3 meter/second, 7.7 ± 1.3 meter/second and 8.3 ±1.1 meter/second, p=0.620). Conclusions: In parallel with the previous 24-week evaluation, results at 2-year follow-up time point indicates that anti-TNF-α therapy does not improve arterial stiffness in patients with AS. References: Arnett FC. Ankylosing Spondylitis. In: Koopman WJ, ed. Arthritis and Allied Condition. Philadelphia: Lippincott Williams and Wilkins, 2001:1317. Karkucak M, Cakırbay H, Capkın E, Topbaş M, Güler M, Tosun M, et al. The prevalance of ankylosing spondylitis in the eastern Black Sea region of Turkey. Eur J Gen Med 2011;8 (1):40-5. Capkın E, Kıris A, Karkucak M, Durmuş I, Gökmen F, Cansu A, et al. Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2011;78(4):378-82. Capkın E, Karkucak M, Kırıs A, Durmus I, Karaman K, Karaca Aet al. Anti-TNF Alpha therapy may not ımprove arterial stiffnes ın patients with ankylosing spondylitis: 24 weeks-follow up. Rheumatology (oxford) 2012; 51(5):910-4. Disclosure of Interest: None Declared